← Back to the library
Depression7 min read

Ketamine

A clear, practical look at ketamine and esketamine for depression: how they differ, what the evidence suggests, and what to discuss with a clinician.

Editorial illustration of a supervised IV setup and glowing neural connections, titled Ketamine for Depression
In this article

When depression has not improved enough with usual treatments, it can be discouraging to wonder what else might help. Ketamine-based treatments have drawn attention because some people experience symptom relief quickly. They are not a fit for everyone, and the different forms of ketamine have different approval and safety requirements. Here is what ketamine is, what research suggests, and what questions may help you explore your options.

What ketamine is—and why it drew interest

Ketamine has been used for decades as an anesthetic. Researchers later found that, at carefully selected doses and in supervised settings, it may ease depression symptoms quickly for some people—particularly people whose depression has not improved enough with other treatments. That possibility has made ketamine an important area of research and a potential option to discuss with a specialist.¹

The word “ketamine” can refer to more than one treatment. IV ketamine is the original racemic medicine and is FDA-approved as an anesthetic, not as a depression medicine; its use for depression is off-label. Esketamine (Spravato) is a related medicine given as a nasal spray and has an FDA-approved indication for treatment-resistant depression in adults, either alone or with an oral antidepressant.²,³

How ketamine may affect brain signaling

Many established antidepressants primarily affect serotonin, norepinephrine, or related signaling systems. Ketamine and esketamine act on the glutamate system, including NMDA receptors. Researchers are still working out exactly how this leads to changes in mood; one area of study is whether ketamine helps strengthen connections between brain cells and supports neuroplasticity. The mechanism is an active research question, not a guarantee of an individual response.¹,³

What the research suggests

Studies of IV ketamine have found that depressive symptoms can improve within hours for some people with treatment-resistant depression. A systematic review of controlled trials found a strong short-term effect, with benefits often greatest during the first day and tending to lessen over the following days. This is encouraging, while also showing why clinicians and researchers continue to study who benefits, how long improvement lasts, and what a safe maintenance plan might look like.¹,⁴

Esketamine has also been tested in clinical trials and is an FDA-approved option for adults with treatment-resistant depression. Approval does not mean it works for everyone. A prescriber can review the evidence alongside your treatment history, goals, other health conditions, and the practical demands of attending supervised sessions.²

Ketamine-based treatments have also been studied in people experiencing suicidal thoughts. For Spravato, the FDA label says effectiveness in preventing suicide or reducing suicidal thoughts or behavior has not been established; treatment does not replace hospitalization or other urgent safety care when needed. If you may be in immediate danger, seek urgent help now.²

What treatment and monitoring can involve

IV ketamine for depression is usually provided by a specialist in a clinical setting, with the dose, schedule, and monitoring determined by the treating clinician. Its use for depression is off-label, and care protocols can differ. Ask the clinic how it screens for safety, monitors you during and after treatment, measures progress, and plans follow-up.

Spravato nasal spray is administered in a certified health-care setting through a restricted safety program. Patients are monitored for at least two hours after each session because of risks such as sedation, dissociation, and increased blood pressure. The treatment team also gives instructions about driving and other activities after a session.²,³

Online or take-home compounded ketamine products are not the same as FDA-approved Spravato. FDA has warned that compounded ketamine products are not FDA-approved and may carry risks, particularly when used without appropriate screening and monitoring. Discuss any product or service with a qualified clinician before considering it.⁵

Side effects and safety questions

Possible effects can include dissociation or feeling detached, dizziness, nausea, sleepiness, and temporary changes in blood pressure or heart rate. The experience varies, and these effects can feel unsettling. Spravato’s prescribing information also warns about sedation, respiratory depression, impaired attention and judgment, and the potential for abuse or misuse.²

Safety depends on the person, the medicine, the dose, and the setting. A clinician should review your health history and other medications, explain what monitoring is provided, and discuss what to do if side effects occur. This is a conversation—not a pass-or-fail checklist—and a history of a particular condition does not automatically tell the whole story about whether a treatment is appropriate.

Questions to bring to your care team

You might ask: Which form of ketamine are you discussing, and is it FDA-approved for my situation? What kind of improvement is realistic to look for, and how will we measure it? What are the risks given my health history and medications? How many visits might be involved, what will monitoring look like, and what is the plan if I improve—or if I do not? What other evidence-based options should I consider alongside it?

Ketamine-based treatments have opened another avenue for some people living with difficult-to-treat depression. Their potential for rapid relief is hopeful, and the limits of the evidence, side effects, and need for appropriate supervision deserve equal care. A thoughtful discussion with a qualified clinician can help you decide whether this is an option worth exploring as part of a broader treatment plan.

Words worth knowing

Neuroplasticity

The brain’s ability to change and adapt through learning, experience, and recovery.

References

  1. 1. National Institute of Mental Health. New Hope for Rapid-Acting Depression Treatment (2024).
  2. 2. U.S. Food and Drug Administration. SPRAVATO (esketamine) Prescribing Information (2025).
  3. 3. National Institute of Mental Health. Cracking the Ketamine Code (2023).
  4. 4. Marcantoni, W. S., et al. (2020). A systematic review and meta-analysis of intravenous ketamine for treatment-resistant depression. PubMed.
  5. 5. U.S. Food and Drug Administration. Compounding Risk Alerts: Ketamine products for psychiatric disorders.

Unlocking the Truth: Ketamine's Impact on Depression

Watch on YouTube

Is Ketamine Treatment the FUTURE of Hospital Care?

Watch on YouTube

Educational content—not medical advice.Find support resources →